Fewer side effects, improved chances of healing: the goal of precision medicine is to provide patients with the most individualized treatment possible. This requires a precise understanding of what is happening at the cellular level. For the first time, researchers at the Technical University of Munich (TUM) have now succeeded in mapping the interactions of 144 active substances with around 8,000 proteins. The results could help to identify previously unknown potential benefits of existing drugs.
Irish biotech collects $75M in Series B to start Phase 3 rare joint tumor trial
SynOx Therapeutics has completed a $75 million Series B raise to advance its monoclonal antibody drug through a registrational trial for a type of non-cancerous
April 23, 2024